

The correlation between polymorphism of interleukin 3 receptor alpha Rs6603272 G/T gene with negative symptoms in Bataknese schizophrenia patients

Dika Asrika Asrul¹, Elmeida Effendy¹, Mustafa Mahmud Amin^{1*}, Vita Camellia³, Zulham Yamamoto²

¹Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, ²Department of Histology, Faculty of Medicine, Universitas Sumatera Utara

ABSTRACT

Aim There are many studies about the correlation between Bataknese and schizophrenia patients, one of the most common ethnic groups in Indonesia. Cytokine and its receptor disorder is one of the scopes of immunology research in schizophrenia. Interleukin 3 (IL-3) is an important cytokine with various biologic roles in immune response. We would like to determine the association between the polymorphism of IL3RA gene with negative symptoms in Bataknese schizophrenia patients.

Methods This study used comparative case control approach. The negative symptoms were assessed using Positive and Negative Syndrome Scale (PANSS). Blood sampling and deoxyribonucleic acid (DNA) isolation used salting out method followed by IL3RA RS6603272 G/T genotype identification using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The data were analysed using χ^2 and Kruskal Wallis test. A $p < 0.05$ was considered statistically significant.

Results Two hundred participants were divided into schizophrenia and healthy control groups evenly. G alleles (49.5% and 50.5%) and GT genotypes (49% and 53%) were the most common alleles and phenotypes in both groups with no significant difference in both groups ($p > 0.05$). The analysis also did not reveal significant correlation between the polymorphism of IL3RA RS6603272 G/T with the negative symptoms of schizophrenia ($p > 0.05$).

Conclusion There was neither significant difference of the presence of G and T alleles, also GG, GT, and TT genotypes between two groups nor the correlation between polymorphism of IL3RA RS6603272 G/T with schizophrenia negative symptoms.

Keywords: Bataknese, IL3RA RS6603272 G/T gene, polymorphism, schizophrenia negative symptoms

INTRODUCTION

Schizophrenia is a chronic and complex neuropsychiatric disorder with a significant impact on the quality of life of patients and their families. Schizophrenia spectrum disorders affect more than 21 million people globally. Seven out of 1,000 people have schizophrenia spectrum disorder during their lifetime, and the symptoms typically appear in the second or third decade of life. The most common onset of schizophrenia is late adolescence and 20s, but males usually have an earlier onset than females (1,2).

The prevalence of schizophrenia had been increasing from 13.1 million in 1990 to 20.9 million cases in 2016, and most cases (70.8% or 14.8 million) were found in the age group of 25 – 54

years old. East Asia and South Asia had the highest schizophrenia cases, about 7.2 million and 4.0 million, respectively, in 2016. National Basic Health Survey in 2018 revealed that Bali and North Sumatra are provinces with the highest schizophrenia prevalence in Indonesia (11% and 5%, respectively). Medan city has a household prevalence of schizophrenia, in which 6.77% of household members had schizophrenia (2-6). Bataknese is one of the most common ethnic groups in Indonesia, particularly in North Sumatra province, and it is between mountains and a lake that has an island in the middle. Bataknese is the oldest Proto-Melayu ethnicity that has retained its language and tradition for a thousand years, and the use of the native language can still be found. Bataknese was divided into six categories: Mandailing, Angkola, Toba, Dairi or Pakpak Dairi, and Simalungun (7,8).

There are various studies about the correlation between genes and schizophrenia (9). A study in the Psychiatry Department Dr. Soetomo Regional General Hospital Surabaya revealed the high prevalence of COMT Val158Met polymorphism (6.7%) with heterozygote alleles of 21,946 (40%), nucleotide variance

*Corresponding author: Mustafa Mahmud

Department of Psychiatry, Faculty of Medicine, University of North Sumatra
Jl. Dr Mansyur No.5, Medan 20155, Sumatera Utara, Indonesia
Phone: +628126001772;

E-mail: mustafa.mahmud@usu.ac.id

Dika Asrika Asrul ORCID: <https://orcid.org/0009-0002-9459-7356>

| Submitted: 30. Aug 2025. Revised: 27. Nov 2025, Accepted: 10. Dec 2025.

This article is an open-access article licensed under CC-BY-NC-ND 4.0 license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

of T substitute to A of 21,971 (3.3%), and G nucleotide variance in the polymorphism of DISC1 gene in schizophrenia patients (10,11). The investigation of the correlation of 174G/C interleukin-6 polymorphisms with schizophrenia in Batak population showed 174G/C polymorphism as a risk factor (12). It was also demonstrated that there was a strong correlation between interferon gamma +874 A/T in schizophrenia. A significant correlation between the polymorphism of the interleukin-10 1082 G/A gene in Bataknese was found (13,14). Various studies have demonstrated significant correlations between genetic variants in schizophrenia patients (13-16).

One of the complexities of schizophrenia is the lack of a central pathophysiology mechanism and a main biological marker. The most common hypothesis is the combination of genetic and environmental factors during early life, which is consistent with the neurodevelopmental hypothesis. Although the schizophrenia gene component has a huge impact, most genetic architectures remain unknown. Schizophrenia is a multifactorial disorder that includes interactions of various susceptible genes, epigenetic processes, and environmental factors (17-19). The dysfunction of the immune system and inflammation contribute to the development of schizophrenia. The specific mechanism regarding the correlation of the neuroimmune system and schizophrenia is being investigated, but it is believed that immune dysregulation may impact brain development and function, potentially contributing to the onset of schizophrenia and its clinical manifestations (20,21).

The disorder of cytokines and their receptors is one of the research focuses regarding immunology in schizophrenia (22). Interleukin-3 (IL-3) is an important cytokine that has various biologic roles in immune response. It affects inflammation response in the adult brain development through the regulation of activated microglia, altering the susceptibility of nerve inflammation, and schizophrenia patients have abnormal serum IL-3 levels. A study in China demonstrated that the polymorphism of the Interleukin-3 Receptor Alpha (IL-3RA) gene was correlated with schizophrenia. Furthermore, the IL-3RA rs6603272 gene also plays a role in schizophrenia (20,22).

The correlation between schizophrenia and nerve degeneration in schizophrenia is a complex study. The exact mechanism is still unknown, but there was evidence that nerve inflammation and degeneration contribute to the negative symptoms in schizophrenia (23). However, the specific cause-and-effect relationship between nerve inflammation, degeneration, and negative symptoms in schizophrenia requires further research for better comprehension (24).

The aim of this study was to investigate the correlation of polymorphism of the IL-3RA gene to negative symptoms in the Bataknese schizophrenia and healthy control groups.

PATIENTS AND METHOD

Patients and study design

The study was conducted in the Prof. Dr. M. Idrem Psychiatry Hospital for case group sampling, Blood Transfusion Unit of Medan City for control group sampling, and Integrated Laboratory of Faculty of Medicine, Universitas Sumatera Utara for gene polymorphism examination between April and July 2024. We wanted to determine the association between the polymorphism of interleukin 3 receptor alpha RS6603272 G/T gene with negative symptoms in Bataknese schizophrenia patients.

Consecutive sampling was applied in this study. The inclusion criteria were as follows: Bataknese patients with schizophrenia whose diagnoses were established according to the third edition of the Guidelines for the Classification and Diagnosis of Mental Health Disorders (25); individuals with Bataknese ancestry up to two generations; aged 18–60 years; presenting predominantly negative symptoms (N score < 21); and who were cooperative and agreed to participate in the study. The exclusion criteria included a history of neurological, endocrine, or autoimmune diseases; a history of alcohol or substance use other than nicotine and caffeine; and current or previous use of immunosuppressive drugs (including corticosteroids or cancer treatment regimens).

The participants were divided into schizophrenia and healthy control groups.

We gave a brief explanation to participants before data collection, and they were asked to sign informed consent. The data were kept confidential.

This study had been approved by the Ethics Committee of Faculty of Medicine of (Number: 362/KEPK/USU/2024).

Methods

After informed consent was obtained, the schizophrenia group was asked to fill out the Bahasa version of the Positive and Negative Syndrome Scale (PANSS) (26). The healthy control group was asked to fill out the Mini International Neuropsychiatric Interview (Mini ICD-10) (27) first to exclude other psychiatric disorders. After that, 7 mL of blood was withdrawn from the median cubital vein in stable schizophrenia patients. For the control group, blood was withdrawn just before the donor process. Blood was examined in the Integrated Laboratory of Medicine Faculty at Universitas Sumatra Utara.

After the blood was withdrawn, it was placed in a vacutainer containing ethylenediamine tetraacetic acid (EDTA) and stored at a temperature of 4–80 °C until deoxyribonucleic acid (DNA) isolation was performed. DNA was isolated using the salting-out method (28). After the DNA isolation, IL3RA RS6603272 G/T genotypes were identified using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method (29). Fragments in 133 base pairs (bp), 25 bp, and 158 bp from IL3RA RS6603272 G/T were amplified using forward primer 5' ACGACCTGTACTTGAACGTTGCCAAGTAGGTGGGC-3, reverse primer: 5-AGCATCCGTTTTGTAGTGAAGAC-3. The PCR products were stored at 37 °C overnight with amplified and digested DNA fragments using the EcoR01091 enzyme and then separated in a 3% agarose gel that was stained with ethidium bromide (24). The examination of DNA concentration, check, and purity were conducted using a nanophotometer n-50 with a mean of 1.8.

Statistical analysis

The data were collected using software statistical analysis with the following steps: variable analysis and presented in the frequency tables. The analysis comprises frequency and percentage. The comparative test (χ^2 test) was conducted to assess the difference in allele and IL-3RA RS6603272 G/T genotype between Bataknese schizophrenia and healthy control groups. The odds ratios were calculated (OR>1 indicates that independent variables were not risk or protective factors; OR=1 indicates that independent variables were not risk or protective factors; and OR<1 indicates that independent variables were

the protective factor of dependent variables). The comparative tests were conducted to determine the correlation between the polymorphism of IL3RA RS6603272 G/T and schizophrenia negative symptoms using the Kruskal-Wallis test.

RESULTS

Two hundred band agarose electrophoresis gels were analysed on the IL3RA RS6603272 G/T gene, and the reading was done using the exact method with Sun et al. (20). No deviation from the Hardy-Weinberg Equilibrium was detected for the three polymorphisms ($p > 0.05$). The analysed demographic characteristics in this study (schizophrenia group) were sex, age, onset of the disease, duration of the disease, and the total PANSS negative symptoms score, while in the healthy control group, the characteristics analysed were sex and age. The categorical data were presented in N (%). In contrast, the numeric data were presented in mean and minimum-maximum value.

Most of our participants in both groups were males, comprising 56 (56%) in the healthy control group and 79 (79%) in the schizophrenia group, respectively. The mean age in the healthy control and schizophrenia groups was 28.89 and 32.38 years, respectively. The median onset age of schizophrenia onset was 27 years, and the median duration was 5 years. Most of the schizophrenia participants in the schizophrenia group were rehospitalization patients who received polytherapy, in which clozapine was the most common antipsychotic drug (98%). Most MoCA-Ina scores indicated moderate cognitive impairment. The median of the PANSS negative symptoms score was 25 (Table 1).

Table 1. Demographic characteristics of two patient groups

Variable	Healthy control (N=100)	Batakese schizophrenia (N=100)
Sex (No; %)		
Male	56 (57)	79 (79)
Female	44 (44)	21 (21)
Age (Mean±SD)	28.89±6.075	32.38±4.4269
	Median (interquartile range)	
Onset (age)	-	27 (14.0-41.00)
Duration (years)	-	5.00 (2.00-21.00)
The total of PANSS negative symptoms score	-	26.93 (21.00-42.00)

PANSS, Positive and Negative Syndrome Scale

The polymorphism of the IL3RA RS6603272 G/T gene consisted of two alleles: G and T. The allele variable was a categorical (nominal) variable and presented in a frequency distribution. The G allele was the most common in both groups. There was no significant difference in G and T allele presence between the two groups ($p > 0.05$), with an odds ratio (OR) of approximately 0.961 (close to 1), indicating that the independent variable was not a risk factor for schizophrenia. The genotype variant of the IL3RA RS6603272 G/T gene consisted of a combination of the G and T alleles, represented by the GT, GG, and TT genotypes. The GT genotype was the most common in the schizophrenia and control groups (49% and 53%, respectively) (Table 2).

The result of binary binomial logistic regression analysis demonstrated no significant difference regarding the presence of the GT genotype in healthy controls and schizophrenia groups, with a $p=0.479$ and OR of 1.288 (GT versus TT). However, based on the OR value, the distribution of GT and GG

Table 2. Differences of IL3RA RS6603272 G/T gene alleles and genotypes in healthy control and schizophrenia groups

Variable	No (%) of patients		p	OR (95% CI)
	Schizophrenia	Healthy control		
IL-3RA RS6603272 Allele				
G	102 (49.5)	104 (50.5)	0.920	0.961 (0.649-1.422)
T	98 (50.5)	96 (49.5)		
Total	200	200		
The Polymorphism IL-3RA RS6603272 Genotypes				
G/T	49 (49)	53 (53)	0.478	1.288 (0.641-2.588)
G/G	26 (26)	26 (26)	0.667	1.190 (0.538-2.636)
T/T	25 (25)	21 (21)		
Total	100	100		

genotypes in healthy controls was a risk factor for schizophrenia. The $p=0.667$ (OR 1.190)-for the GT and GG genotypes was found. This result indicates that there were no significant differences in the presence of the GG genotype between the two groups, and the OR value revealed that the difference in the distribution of GG and TT genotypes was not considered a risk factor for schizophrenia (Table 2).

Batakese schizophrenia patients with mean scores of 27.57, 24.85, and 25.84 for the GG, GT, and TT genotypes, respectively, with $p = 0.762$ (> 0.05), were found. Furthermore, the mean score of the Batakese schizophrenia group with G and T alleles was 27.41 and 26.95, respectively, with a $p=0.308$ (> 0.05). It can be concluded that there is no significant correlation between the polymorphism of IL3RA RS6603272 G/T with negative symptoms in the Batakese schizophrenia group (Table 3).

Table 3. Correlation between T genotype and polymorphism of IL-3 RS 6603272 G/T gene with negative symptoms in schizophrenia patients

Variable	Genes	N	Mean	p
Genotypes (N=100)	GG	49	27.57	0.763
	GT	26	24.58	
	TT	25	25.84	
Allele (N=200)	G	102	27.41	0.308
	T	98	26.95	

PANSS, Positive and Negative Syndrome Scale




Figure 1. Agarose electrophoresis gel of the polymorphism of IL3RA RS6603272 G/T Gene

1st row = marker (M), base pair 25 = base pair ladder, base pair 158 = allele G, base pair 23 and 133 = T allele; 2nd row = GG genotype; 3rd row = GT genotype, 6th row = TT genotype

DISCUSSION

Most participants in this study were males with an age range of 23 – 50 years in the schizophrenia group. It is similar with previous studies (1,19,20) although there are opposite results with no significant prevalence of schizophrenia between males and females (30). The reason for higher schizophrenia prevalence in males may be due to the lower medication adherence and higher relapse rate in males, as well as a relative difference in help-seeking between males and females, and a higher substance misuse rate in males (31,32). The analysis of age of onset in this study was in line with other studies which found that the most common onset of schizophrenia was in the age group of 19 to 51 years (33). An epidemiology study from Spain also found that the highest prevalence of schizophrenia was found in males in the age group of 35- 54 years (1,33).

There was no significant difference in the presence of the allele between the two groups. However, a study in China found a significant difference in alleles between schizophrenia and healthy control groups, in which the T allele is more common in schizophrenia patients compared to healthy controls, with a significant correlation (22). The inconsistency between those studies may be due to different inclusion criteria and ethnicity. Furthermore, environmental and lifestyle factors may play an important role in schizophrenia development, leading to the variance in results between studies. Interleukin-3 may contribute to various immunological disorders, consistent with the hypothesis that cytokine disorders in schizophrenia have a strong genetic basis. However, the functional aspect of the rs6604272 polymorphism in IL-3RA is still unknown. Further studies are required to determine if this gene polymorphism is associated with increased peripheral IL-3 value in schizophrenia patients, particularly chronic patients (33-35).

We found no significant difference in the genotype polymorphism of the IL3RA RS6603272 G/T gene between the two groups. It was not consistent with previous studies that demonstrated a correlation between the polymorphism of the IL3RA RS6603272 G/T gene and schizophrenia prevalence. The inconsistency between these studies may be due to differences in inclusion criteria, sample size, and ethnicity. Additionally, the increased serum IL-3RA level was confirmed in the studies prior to the polymorphism study. The different results of similar polymorphism may appear due to several factors, such as different effects from similar polymorphism genetic factors, which depend on the individual's whole genetic arrangement, also environmental factors, such as dietary habits, lifestyle, toxic exposure, and stress (22,36). The epigenetic modification role, such as DNA methylation and histone modification, can alter gene expression without altering the DNA sequence (37). The polymorphism regarding the disease risk may only express those risks in certain conditions. These single or combination factors may cause similar polymorphism with different results in different individuals or conditions. The different findings in this study may be influenced by factors such as varying standards for antipsychotic drugs, sample size, and differing inclusion and exclusion criteria across studies (38).

The analysis revealed no significant correlation between IL-3RA RS6603272 G/T gene alleles and genotypes with schizophrenia negative symptoms. This study is the first to determine the correlation between the polymorphism of the IL3RA RS6603272 G/T gene and negative symptoms. However, numerous studies have investigated the correlation between

gene polymorphism and negative symptoms, particularly those involving immune-related genes. Several studies have reported correlated results, finding a significant positive correlation between immune-related genes and schizophrenia negative symptoms, specifically the polymorphisms of IL-1 β , IL-2, IL-6, and TNF- α genes (39,40).

Several studies also demonstrated the correlation between peripheral inflammation biomarkers and negative symptoms. An increased inflammation cascade, characterized by heightened immune activity, pro-inflammatory cytokine production, and oxidative stress, was found in schizophrenia patients. The interaction between these factors contributes to serotonergic, dopaminergic, and glutamatergic neurotransmission disorders, leading to negative symptoms (21,40,41). Peripheral immune response reflects central neuroimmune status; therefore, systemic cytokine concentration is more relevant to reflect how inflammation leads to a specific symptom profile in schizophrenia. The balance between peripheral Th1 and Th2 inflammatory responses and cytokine production is crucial for efficient immune response; therefore, their imbalance may affect Th2 differentiation and secretion. Reportedly, increased IL-3 serum levels in schizophrenia patients, particularly in chronic patients, and their correlation analysis demonstrated the correlation between increased serum IL-3 levels and negative symptoms score. A genetic study also demonstrated that IL-3 and IL-3RA genes are located near the schizophrenia-associated genetic marker in pseudo-autosomal region (PAR1) from X and Y chromosomes, in which the abnormality of IL-3 and its receptor contributes to increased granulocyte-macrophage colony stimulating factor (GM-CSF), which encourages inflammation, and may play a role in the manifestation of schizophrenia symptoms (21,38,42).

Previous studies supported the hypothesis that pro-inflammatory cytokines in the peripheral body system increased in schizophrenia. However, the manifestation of schizophrenia symptoms varied and was affected by the complex interaction between genetic, epigenetic, environmental, and neuronal developmental factors. These interactions may lead to similar polymorphism in patients with different symptoms. Each person has a unique genetic arrangement, and other genetic variants may interact with polymorphisms, altering their effects. This interaction may alter how certain polymorphisms contribute to the development of symptoms. Schizophrenia-related polymorphism can lead to different symptom profiles, depending on certain life events in the environmental context (22,38,43).

This study was the first in Indonesia and Medan to investigate one ethnic group, the Batakese, specifically reporting the demography of genotypes and alleles of the polymorphism of the IL3RA RS6603272 G/T gene in North Sumatra. This study may be the foundation of future studies regarding the correlation polymorphism of gene for another ethnic group in Indonesia or other countries with schizophrenia to extend the knowledge between gene and schizophrenia.

Our study has several limitations such as the confounding factors of cytokines that cannot be fully controlled, and the small sample size.

In conclusion, there was neither significant difference regarding the presence of G and T alleles also GG, GT, and TT genotypes between both groups nor significant correlation between the polymorphism of IL3RA RS6603272 G/T allele with negative symptoms of schizophrenia.

AUTHORS CONTRIBUTION

Conceptualization D.A.A, E.E, and M.M.A; methodology, D.A.A, E.E, and M.M.A; software, D.A.A; validation D.A.A; formal analysis, D.A.A and E.E; investigation. D.A.A; resources D.A.A and E.E; data curation D.A.A and E.E; writing (first draft) D.A.A and E.E; writing (review and editing), D.A.A, E.E, M.M.A, V.C, Z.Y; visualization D.A.A, E.E, M.M.A, V.C, Z.Y; study registration and funding, D.A.A.

ACKNOWLEDGMENT

This study has gained ethical clearance from the Ethics Committee of Faculty of Medicine, Universitas of Sumatera Utara

REFERENCES

- Orrico-Sánchez A, López-Lacort M, Munõz-Quiles C, Sanfélix-Gimeno G, Diéz-Domingo J. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. *BMC Psychiatry* 2020; 20(1):149. doi: <https://doi.org/10.1186/s12888-020-02538-8>
- World Health Organization. Schizophrenia. 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia?gclid=Cj0KCQIAtOmsBhCnARIsAGPa5yYQtVCx-GYgqvo5yuTcAaIHcBiGj9jni4bonl3SNKKc3JWFmZzk-tAMUaAtR2EALw_wcB (accessed: January 7, 2024).
- Subramaniam M, Abdin E, Vaingankar JA, Sambasivam R, Zhang YJ, Shafie S, et al. Lifetime Prevalence and Correlates of Schizophrenia and Other Psychotic Disorders in Singapore. *Front Psychiatry* 2021; 12:650674. doi: <https://doi.org/10.3389/fpsy.2021.650674>
- Health Research and Development Institution. 2018 Basic National Health Research Report in North Sumatera. Health Research and Development Institution (Badan Penelitian dan Pengembangan Kesehatan. LAPORAN RISKESDAS SUMUT 2018. Badan Penelitian dan Pengembangan Kesehatan) [in Bahasa], 2018.
- Laila NH, Mahkota R, Shivalli S, Bantas K, Krianto T. Factors associated with pasung (physical restraint and confinement) of schizophrenia patients in Bogor regency, West Java Province, Indonesia 2017. *BMC Psychiatry* 2019; 19(1):L162. <https://doi.org/10.1186/s12888-019-2138-z>
- Indonesian Health Ministry. The Main Results of 2018 Basic National Health Research (Kementerian Kesehatan Republik Indonesia. Hasil Utama Riskesdas 2018. Kementerian Kesehatan Republik Indonesia) [in Bahasa]. Ministry of Health Republic Indonesia; 2018.
- Sihombing AA. The Perspective of Cohesion and Harmony. Learning Batak Toba Culture through “Dalihan Na Tolu Philosophy” (Mengenal Budaya Batak Toba Melalui Falsafah “Dalihan Na Tolu” Perspektif Kohesi dan Kerukunan. J Lektur keagamaan) [in Bahasa]. *Journal of Religion lecture* 2018; 31;16(2):347–71. <http://dx.doi.org/10.31291/jlk.v16i2.553>.
- Harahap HJP. Ethnic Dynamics in North Sumatra. *Budapest International Research and Critics Institute-Journal (BIRCI-Journal)*. 2021; 4(4):12736–46. <https://doi.org/10.33258/birci.v4i4.3333>
- Irmansyah, Schwab SG, Heriani, Handoko HY, Kusumawardhani A, Widyawati I, et al. Genome-wide scan in 124 Indonesian sib-pair families with schizophrenia reveals genome-wide significant linkage to a locus on chromosome 3p26-21. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2008; 147B(7):1245–52. <https://doi.org/10.1002/ajmg.b.30763>
- Ichsan PG, Maria MM, Yulianti E, Zulaikah A, Budi SZ, Dyah KWC, et al. Detection of COMTVal158Met Gene Polymorphism in Chronic Schizophrenic Patients at Psychiatric Unit of DR. Soetomo Hospital Surabaya, East Java, Indonesia: Scitepress. 2018: 117–22. <https://doi.org/10.5220/0007333901170122>
- Prabowo GI, Maramis MM, Yulianti E, Zulaikah A, Syulthoni ZB, Margono HM, et al. The frequency of DISC1 Leu607Phe gene polymorphism in schizophrenia patients at Dr. Soetomo General Hospital Surabaya. *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)* 2018; 50(01):15–23. <http://dx.doi.org/10.19106/JMedSci005001201802>
- Saragih M, Amin MM, Effendy E. Association of polymorphism -174g/c interleukin-6 (IL-6) and schizophrenia in bataknese population. *Open Access Maced J Med Sci* 2021; 9(T3):56–9. <https://doi.org/10.3889/oam-jms.2021.6320>
- Effendy E, Loebis B, Amir N, Siregar Y. SN-P8NRG433E1006 Neuregulin -1 Genetic Variation in Bataks Ethnic with Schizophrenia Paranoid and Healthy Control. *Bali Med. J.* 2014; 3(2): 58-64. <https://doi.org/10.15562/bmj.v3i2.75>
- Amin MM, Husada MS, Idaiani S, Effendy E, Nasution S, Purnama SD. The Effect of Interleukin-2 -330 T/G Polymorphism in People with Schizophrenia Among The Batak and Javanese Ethnic Groups. *Med Arch* 2023; 77(5):363–9. <https://doi.org/10.15562/bmj.v3i2.75>
- Banurea MA, Amin MM, Effendy E. Differences in Interleukin-4-590 C/T Variants Between Batak People with Schizophrenia and Healthy Control. In: *Proceedings of the 6th International Conference of Neuroscience, Neurology and Psychiatry Universitas Sumatera Utara (ICONAP 2023)* [Internet]. Atlantis Press; 2023. p. 121–5. Available from: https://doi.org/10.2991/978-94-6463-310-8_18

16. Sinurat JA, Amin MM, Husada MS. Association of the MCP-1 -2518 A/G Polymorphism with Schizophrenia Risk: Insights from a Batak Ethnic Group Study. In: Proceedings of the 6th International Conference of Neuroscience, Neurology and Psychiatry Universitas Sumatera Utara (ICONAP 2023) [Internet]. Atlantis Press; 2023. p. 104–9. https://doi.org/10.2991/978-94-6463-310-8_15
17. Zamanpoor M. Schizophrenia in a genomic era: A review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Vol. 30, *Psychiatric Genetics*. Lippincott Williams and Wilkins; 2020. p. 1–9. <https://doi.org/10.1097/YPG.0000000000000245>
18. Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Vol. 10, *Frontiers in Psychiatry*. Frontiers Media S.A.; 2019. <https://doi.org/10.3389/fpsy.2019.00892>
19. Trifu S, Kohn B, Vlasie A, Patrichi BE. Genetics of schizophrenia (Review). *Exp Ther Med* [Internet]. 2020 Jul 7; Available from: <http://www.spandidos-publications.com/10.3892/etm.2020.8973>
20. Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, et al. Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. *Neurosci Lett*. 2008 Jul 25;440(1):35–7. <https://doi.org/10.1016/j.neulet.2008.05.029>
21. Goldsmith DR, Rapaport MH. Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. *Front Psychiatry*. 2020 Feb 20;11:46. <https://doi.org/10.3389/fpsy.2020.00046>
22. Xiu MH, Lin CG, Tian L, Tan YL, Chen J, Chen S, et al. Increased IL-3 serum levels in chronic patients with schizophrenia: Associated with psychopathology. *Psychiatry Res*. 2015 Sep 30;229(1–2):225–9. <https://doi.org/10.1016/j.psychres.2015.07.029>
23. Goldsmith DR, Massa N, Miller BJ, Miller AH, Duncan E. The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia. *NPJ Schizophr*. 2021 Oct 20;7(1):50. <https://doi.org/10.1038/s41537-021-00179-8>
24. Strauss GP, Esfahlani FZ, Kirkpatrick B, Allen DN, Gold JM, Visser KF, et al. Network Analysis Reveals Which Negative Symptom Domains Are Most Central in Schizophrenia vs Bipolar Disorder. *Schizophr Bull*. 2019 Oct 24;45(6):1319–30. <https://doi.org/10.1093/schbul/sby168>
25. Ministry of Health Republic Indonesia. The Guideline of Classification and Diagnosis of Mental Health Disorders (Departemen Kesehatan R.I. Pedoman Penggolongan dan Diagnosis Gangguan Jiwa. Edisi 3. Jakarta: Departemen Kesehatan Republik Indonesia). 3rd Edition. Jakarta: Ministry of Health Republic Indonesia; 1993. 425 p.
26. Surya Yudhantara D, Septiandy Runtuk K, Wijovi F, Alfa Cipta D. Association between Brain-derived Neurotrophic Factor (BDNF) Val66Met polymorphism and Clinical Outcomes as Measured with PANSS Scale in Patients With Schizophrenia in Two Psychiatric Centres in East Java – Indonesia. *Arch Psychiatry Res*. 2024 Jul 2;60(2):91–8. <https://doi.org/10.20471/june.2024.60.02.01>
27. Modak A, Jani R, Jani S, Mammis A. Psychiatric screening for spinal cord stimulation for complex regional pain syndrome: A literature review and practical recommendations for implementation. *Interdisciplinary Neurosurgery*. 2023 Mar;31:101633. <https://doi.org/10.1016/j.inat.2022.101633>
28. Ammar H, Chadli Z, Mhalla A, Khoudja S, Hannachi I, Alshaikheid M, et al. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. *Pharmacogenomics J*. 2021 Oct;21(5):551–8. <https://doi.org/10.1038/s41397-021-00231-x>
29. Ambrozová L, Zeman T, Janout V, Janoutová J, Lochman J, Šerý O. Association between polymorphism rs2421943 of the INSULIN-DEGRADING enzyme and schizophrenia: Preliminary report. *Clinical Laboratory Analysis*. 2023 Jul;37(13–14):e24949. <https://doi.org/10.1002/jcla.24949>
30. Seeman MV, González-Rodríguez A. Stratification by Sex and Hormone Level When Contrasting Men and Women in Schizophrenia Trials Will Improve Personalized Treatment. *J Pers Med*. 2021 Sep 18;11(9):929. <https://doi.org/10.3390/jpm11090929>
31. Sommer IE, Tiihonen J, van Mourik A, Tanskanen A, Taipale H. The clinical course of schizophrenia in women and men—a nation-wide cohort study. *NPJ Schizophr*. 2020 May 1;6(1):12. <https://doi.org/10.1038/s41537-020-0102-z>
32. He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. *Epidemiol Psychiatr Sci*. 2020 Jan 13;29:e91. <https://doi.org/10.1017/S2045796019000891>
33. Nasution S, Effendy E, Amin MM. Candidate IL-1β -511C/T Polymorphism in Schizophrenia Patients in Batak Tribe. In: Proceedings of the 6th International Conference of Neuroscience, Neurology and Psychiatry Universitas Sumatera Utara (ICONAP 2023) [Internet]. Atlantis Press; 2023. p. 107–12.
34. Rodrigues-Amorim D, Rivera-Baltanás T, Spuch C, Caruncho HJ, González-Fernandez Á, Olivares JM, et al. Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. *Schizophr Res*. 2018;197:19–33. <https://doi.org/10.1016/j.schres.2017.11.023>
35. Tanrikulu A. Genetic basis of schizophrenia: Basic hypothesis pathways and gene functions. *Demiroglu Science University Florence Nightingale Transplantation Journal*. 2020 Dec 22;5(1–2):13–21. <https://doi.org/10.5606/dsuf-njt.2020.012>
36. Wei J, Li H, Jin S, Li P, Ju G, et al. A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population. *Brain Res*. 2009 May 1;1268:13–6. <https://doi.org/10.1016/j.brainres.2009.02.071>
37. Richetto J, Meyer U. Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability. *Biol Psychiatry*. 2021 Feb;89(3):215–26. <https://doi.org/10.1016/j.biopsych.2020.03.008>

38. Dunleavy C, Elsworth RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. *Acta Psychiatr Scand.* 2022 Jul 5;146(1):6–20. <https://doi.org/10.1111/acps.13416>
39. Xavier RM, Vorderstrasse A. Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia. *Biol Res Nurs.* 2017 Oct 10;19(5):559–75. <https://doi.org/10.1177/1099800417715907>
40. Mak M, Misiak B, Frydecka D, Pełka-Wysiecka J, Kucharska-Mazur J, Samochowiec A, et al. Polymorphisms in immune-inflammatory response genes and the risk of deficit schizophrenia. *Schizophr Res.* 2018 Mar;193:359–63. <https://doi.org/10.1016/j.schres.2017.06.050>
41. Comer AL, Carrier M, Tremblay MÈ, Cruz-Martín A. The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation. Vol. 14, *Frontiers in Cellular Neuroscience*. Frontiers Media S.A.; 2020. <https://doi.org/10.3389/fncel.2020.00274>
42. Lencz T, Morgan T V, Athanasiou M, Dain B, Reed CR, Kane JM, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. *Mol Psychiatry.* 2007 Jun 1;12(6):572–80. <https://doi.org/10.1038/sj.mp.4001983>
43. Reale M, Costantini E, Greig NH. Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. *Front Psychiatry.* 2021 Mar 5;12. <https://doi.org/10.3389/fpsy.2021.536257>

Publisher's Note Publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations